• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (NY: MAIA )

    3.310 -0.090 (-2.65%)
    Official Closing Price Updated: 8:00 PM EDT, Jul 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 107,995
    Open 3.470
    Bid (Size) 3.430 (25)
    Ask (Size) 3.510 (1)
    Prev. Close 3.400
    Today's Range 3.310 - 3.530
    52wk Range 0.8200 - 5.990
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MAIA Biotechnology (MAIA) is one of the earliest pioneers of telomere targeting as a therapeutic strategy
    Via AB Newswire
    Exposures Product Safety
    MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
    MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six... 
    Via Benzinga

    Performance

    YTD
    +178.15%
    +178.15%
    1 Month
    -0.60%
    -0.60%
    3 Month
    +3.12%
    +3.12%
    6 Month
    +125.17%
    +125.17%
    1 Year
    +43.91%
    +43.91%

    More News

    Read More
    Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
    From MAIA Biotechnology, Inc.
    Via Business Wire
    FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
    Via AB Newswire
    Exposures COVID-19 Product Safety
    Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
    From MAIA Biotechnology, Inc.
    Via Business Wire
    New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
    Via News Direct
    Topics Death
    Exposures Death
    MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
    Via AB Newswire
    MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
    From MAIA Biotechnology, Inc.
    Via Business Wire
    Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
    Via AB Newswire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
    From MAIA Biotechnology, Inc.
    Via Business Wire
    MAIA Biotechnology (MAIA) to Showcase Groundbreaking Telomere-Targeting Cancer Treatments at BIO International Convention 2024
    Via AB Newswire
    MAIA Biotechnology Inc (MAIA) Stock Surges as Company Prepares to Present Promising Data at BIO International Convention
    Via AB Newswire
    MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market
    Via News Direct
    MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
    Via AB Newswire
    MAIA Biotechnology to Present at the BIO International Convention 2024
    From MAIA Biotechnology, Inc.
    Via Business Wire
    MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
    From MAIA Biotechnology, Inc.
    Via Business Wire
    MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024
    Via InvestorPlace
    MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
    From MAIA Biotechnology, Inc.
    Via Business Wire
    MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
    From MAIA Biotechnology, Inc.
    Via Business Wire
    MAIA Biotechnology Announces $1.00 Million Private Placement
    From MAIA Biotechnology, Inc.
    Via Business Wire
    MAIA Biotechnology to Present at Two Investor Conferences in April 2024
    From MAIA Biotechnology, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.